Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBI3032 in Healthy Participants

NCT07120425 is registered in ClinicalTrials.gov with Fortvita Biologics (USA)Inc. as lead sponsor.

NCT NCT07120425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07120425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBI3032 in Healthy Participants
Lead sponsor
Fortvita Biologics (USA)Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 10, 2025
Completion date
November 13, 2025
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy